Trial | NCT00559169  Report issue

Title

Verapamil and Catamenial Epilepsy
Study of Verapamil in Refractory Catamenial Epilepsy

  • Phase

    N/A

  • Study Type

    Interventional

  • Status

    Withdrawn

  • Intervention/Treatment

    verapamil ...

  • Study Participants

    12
One in 3 epilepsy patients have refractory seizures. This drug resistance is likely related to the over expression of multidrug resistance proteins (MDR). Progesterone is a known inhibitor of MDRs and the low level of this hormone during the menstrual cycle may exacerbate seizures, perhaps explaining catamenial epilepsy; i.e. seizures occurring during the menstrual cycle. Verapamil suppresses seizures in animal models of epilepsy perhaps by inhibiting MDRs and thus may help patients with refractory seizures. If the study shows improved seizure control, the results will help establish the role of MDRs in refractory epilepsy.
Study Started
Feb 28
2009
Study Completion
Dec 31
2010
Anticipated
Last Update
Apr 08
2010
Estimate

Drug verapamil hyrochloride

80 mg daily by mouth, 5 days prior to menses for 3 months

  • Other names: apo-verap, isoptin

Criteria 

Inclusion Criteria:

females
at least 2 seizures per month
more than 50% of the seizures occur 7 days before or 7 days after the onset of menses
patient of the Toronto Western Hospital Epilepsy Clinic

Exclusion Criteria:

cardiovascular history
No Results Posted